• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Vanda Pharmaceuticals Inc. - Common Stock (NQ:VNDA)

    5.440 +0.110 (+2.06%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 25, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 876,255
    Open 5.340
    Bid (Size) 5.390 (200)
    Ask (Size) 5.600 (600)
    Prev. Close 5.330
    Today's Range 5.340 - 5.500
    52wk Range 4.270 - 9.940
    Shares Outstanding 55,638,166
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Vanda (VNDA) Q2 2026 Earnings Call Transcript ↗
    Fanapt surges 23% as Vanda expands psychiatry franchise amid pipeline progress. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Vanda Pharmaceuticals Q2 Earnings Call Highlights ↗
    Vanda Pharmaceuticals (NASDAQ:VNDA) reported second-quarter 2026 revenue of $50.5 million, down 4% from a year earlier, as growth in Fanapt and PONVORY was offset by lower HETLIOZ sales amid generic... 
    Via MarketBeat
    Topics Earnings

    Performance

    YTD
    -34.1%
    -34.1%
    1 Month
    +4.2%
    +4.2%
    3 Month
    -12.5%
    -12.5%
    6 Month
    -33.3%
    -33.3%
    1 Year
    +18.0%
    +18.0%

    More News

    Read More
    News headline image
    Vanda (VNDA) Q1 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings Intellectual Property
    VANDA PHARMACEUTICALS INC (NASDAQ:VNDA) Misses Q1 2026 Estimates as Top-Line Growth Slows ↗
    Via Chartmill
    Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? ↗
    Via Stocktwits
    Vanda Pharmaceuticals Inc (NASDAQ:VNDA) Stock Plummets 9.8% After Mixed Q4 2025 Earnings Report ↗
    Via Chartmill
    Curious about the stocks that are showing activity after the closing bell on Friday? ↗
    Via Chartmill
    News headline image
    Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections ↗
    Via Stocktwits
    News headline image
    Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder ↗
    Via Stocktwits
    In today's session, these stocks are experiencing unusual volume. ↗
    Via Chartmill
    Vanda Stock Drop 10% Premarket After FDA Rejects Jet Lag Drug Application ↗
    Via Stocktwits
    Let's take a look at the stocks that are in motion in today's session. ↗
    Via Chartmill
    Here are the top movers in Monday's session. ↗
    Via Chartmill
    These stocks are gapping in today's session ↗
    Via Chartmill
    These stocks are moving in today's pre-market session ↗
    Via Chartmill
    News headline image
    Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗
    Via Stocktwits
    Topics Artificial Intelligence ETFs Government
    News headline image
    VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? ↗
    Via Stocktwits
    News headline image
    VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug ↗
    Via Stocktwits
    News headline image
    Vanda Stock Draws Heavy Buzz Ahead Of FDA Verdict On Bysanti For Bipolar, Schizophrenia ↗
    Via Stocktwits
    News headline image
    Vanda (VNDA) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
    From Pomerantz LLP
    Via GlobeNewswire
    Get insights into the top gainers and losers of Thursday's pre-market session. ↗
    Via Chartmill

    Frequently Asked Questions

    Is Vanda Pharmaceuticals Inc. - Common Stock publicly traded?
    Yes, Vanda Pharmaceuticals Inc. - Common Stock is publicly traded.
    What exchange does Vanda Pharmaceuticals Inc. - Common Stock trade on?
    Vanda Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Vanda Pharmaceuticals Inc. - Common Stock?
    The ticker symbol for Vanda Pharmaceuticals Inc. - Common Stock is VNDA on the Nasdaq Stock Market
    What is the current price of Vanda Pharmaceuticals Inc. - Common Stock?
    The current price of Vanda Pharmaceuticals Inc. - Common Stock is 5.440
    When was Vanda Pharmaceuticals Inc. - Common Stock last traded?
    The last trade of Vanda Pharmaceuticals Inc. - Common Stock was at 08/25/26 04:00 PM ET
    What is the market capitalization of Vanda Pharmaceuticals Inc. - Common Stock?
    The market capitalization of Vanda Pharmaceuticals Inc. - Common Stock is 302.67M
    How many shares of Vanda Pharmaceuticals Inc. - Common Stock are outstanding?
    Vanda Pharmaceuticals Inc. - Common Stock has 303M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.